The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: A meta-analysis

American Journal of Gastroenterology

Volumn 94, Issue 7, 1999, Pages 1751-1759

  Van Der Wouden, E J ^a   Thijs, J C ^a   Van Zwet, A A ^b   Sluiter, W J ^c   Kleibeuker, J H ^c  

^a Bethesda Hospital   (Netherlands)

^b Public Health Service of Groningen   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH NITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; ORNIDAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BIOPSY; BREATH ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033015306     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00258-0     Document Type: Review

References (116)

1. Van der Hulst R.W.M., Keller J.J., Rauws E.A.J., et al. Treatment of Helicobacter pylori infection A review of the world literature . Helicobacter. 1:1996;6-19.
2. Glupczynski Y., Burette A., De Koster E., et al. Metronidazole resistance in Helicobacter pylori. Lancet. 1:1990;976-977. (letter).
3. Glupczynski Y. In vitro susceptibility of Helicobacter pylori to antimicrobial agents Basis for treatment or microbiologists' obsession? Zbl Bact. 280:1993;227-238.
4. Batnavala N., Davies G.R., Abdi Y., et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London Relation with previous nitroimidazole exposure and gastroduodenal disease . Gut. 35:1994;1562-1566.
5. Reddy R., Osato M., Gutiérrez O., et al. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US. Gastroenterology. 110:1996;A238. (abstract).
6. Morton D., Ahmed R., Alley R., et al. Helicobacter pylori antimicrobial susceptibilities A tale of two cities . Gastroenterology. 114:1998;A954-A955. (abstract).
7. Xia H.X., Keane C.T., O'Morain C.A. A 5-year survey of metronidazole and claritromycin resistance in clinical isolates of Helicobacter pylori. Gut. 39:1996;A6. (abstract).
8. Lopez-Brea M., Domingo D., Sanchez I., et al. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother. 40:1997;279-281.
9. Weissfeld A.S., Simmons D.E., Vance P.H., et al. In vitro susceptibility of pre-treatment isolates of Helicobacter pylori from two multicenter United States clinical trials. Gastroenterology. 110:1996;A295. (abstract).
10. Van der Wouden E.J., Van Zwet A.A., Thijs J.C., et al. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis. 3:1997;385-389.
11. Morton D., Bardhan K.D. A six-year assessment of tinidazole, metronidazole, clarithromycin, tetracycline and amoxicillin resistance in Helicobacter pylori isolates A rising tide of antibiotic resistance? Gastroenterology. 114:1998;A907. (abstract).
12. Bateson M.C. Helicobacter pylori eradication. Aliment Pharmacol Ther. 11:1997;1001. (letter).
13. Harris A., Misiewicz J.J. Treating Helicobacter pylori - The best is yet to come? Gut. 39:1996;781-783. (editorial).
14. Roda E., Festi D., Mazzella G., et al. Meeting report Update on Helicobacter pylori research: Eradication . Eur J Gastroenterol Hepatol. 9:1997;613-628.
15. Walt R.P. Metronidazole resistant H. pylori of questionable clinical importance. Lancet. ii:1996;489-490. (letter).
16. De Boer W.A., Tytgat G.N.J. How to treat Helicobacter pylori infection - Should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol. 8:1996;709-716.
17. Misiewicz J.J. Management of Helicobacter pylori-related disorders. Eur J Gastroenterol Hepatol. 9:(suppl 1):1997;17-21.
18. Goddard A.F., Logan R.P.H. Antimicrobial resistance and Helicobacter pylori. J Antimicrob chemoth. 37:1996;639-643.
19. Fennerty M.B. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. Am J Gastroenterol. 93:1998;2-3. (editorial).
20. Tytgat G.N.J. Antimicrobial therapy for Helicobacter pylori infection. Helicobacter. 2:1997;S81-S88.
21. Fleiss J.L. The statistical basis of meta-analysis. Stat Meth Med Res. 2:1993;121-145.
22. Morris J.A., Gardner M.J. Calculating confidence intervals for relative risks (odds ratios) and standardized ratios and rates. Br Med J. 296:1988;1313-1316.
23. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 315:1997;629-634.
24. Cappelleri J.C., Ionnaidis J.P.A., Schmid C.H., et al. Large trials vs meta-analysis of smaller trials. How do their results compare? JAMA. 276:1996;1332-1338.
25. Stuck A.E., Siu A.L., Wieland G.D., et al. Comprehensive geriatric assessment A meta-analysis of controlled trials . Lancet. 42:1993;1032-1036.
26. Statistical annex Statistical aspects of clinical trials in Helicobacter pylori infection . Gut. 41:(suppl 2):1997;S19-S23.
27. Bell G.D., Powell K.U., Burridge S.M., et al. Helicobacter pylori eradication Efficacy and side effect profile of a combination of omeprazole amoxicillin and metronidazole compared with four alternative regimens . Q J Med. 86:1993;743-750.
28. De Boer W.A., Driessen W., Jansz A., et al. Effect of acid suppression on the efficacy of treatment for Helicobacter pylori infection. Lancet. 345:1995;817-820.
29. Lerang F., Moum B., Ragnhildtstveit E., et al. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection A prospective randomized 1-year follow up study . Am J Gastroenterol. 92:1997;653-658.
30. Lerang F, Moum B, Ragnhildstveit E, et al. Simple, efficient and tolerable triple therapy with omeprazole for Helicobacter pylori infection. United European Gastroenterology Week 1995:A550 (abstract).
31. Lerang F., Moum B., Ragnhildstveit E., et al. Significance of metronidazole resistance in Helicobacter pylori eradication. Scand J Gastroenterol. 30:(suppl 209):1995;28. (abstract).
32. Burette A., Glupczynski Y., De Prez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur J Gastroenterol Hepatol. 4:1992;817-824.
33. Lian J.X., Carrick J., Lee A., et al. Metronidazole resistance significantly affects eradication of H. pylori infection. Gastroenterology. 104:1993;A133. (abstract).
34. Rautelin H., Seppälla K., Renkonen O.V., et al. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 36:1992;163-166.
35. Van Zwet A.A., Thijs J.C., Oom J.A.J., et al. Failure to eradicate Helicobacter pylori in patients with metronidazole resistant strains. Eur J Gastroenterol Hepatol. 5:1993;185-186. (letter).
36. Midolo P.D., Lambert J.R., Turnidge J. Metronidazole resistance A predictor of failure of Helicobacter pylori eradication by triple therapy . J Gastroenterol Hepatol. 11:1996;290-292.
37. Xia H., Daw M.A., Sant S., et al. Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. Eur J Gastroenterol Hepatol. 5:1993;141-144.
38. Zala G., Flury R., Wust, et al. Efficacy of triple therapy to eradicate H. pylori after failure of omeprazole and amoxicillin. Gastroenterology. 108:1995;A266. (abstract).
39. Daskalopoulos G., Lian J.X., Ho Y.Y. Randomized controlled study comparing triple therapy containing a proton pump inhibitor to standard triple therapy for the eradication of H. pylori. Gastroenterology. 108:1995;A79. (abstract).
40. Noach L.A., Langenberg W.L., Bertola M.A., et al. Impact of metronidazole on the eradication of H. pylori. Scand J Infect Dis. 26:1994;321-327.
41. Logan R.P.H., Gummett P.A., Misiewicz J.J., et al. One week eradication regimen for Helicobacter pylori. Lancet. 338:1991;1249-1252.
42. Fraser A.G., Moore L., Ali M.R., et al. An audit of low dose triple therapy for the eradication of Helicobacter pylori. N Z Med J. 109:1996;290-292.
43. Thijs J.C., Van Zwet A.A., Moolenaar W., et al. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection A multicenter, prospective, randomized controlled study of efficacy and side effects . Am J Gastroenterol. 91:1996;93-97.
44. Borody T., Andrews P., Brandl S., et al. Relevance of in-vitro metronidazole resistance to H. pylori eradication and eradication failure. Gastroenterology. 104:1993;A44. (abstract).
45. Logan R.P.H., Gummett P.A., Misiewicz J.J., et al. One week anti-Helicobacter pylori treatment for duodenal ulcer. Gut. 35:1994;15-18.
46. Lerang F, Moum B, Ragnhildstveit E, et al. Simple low cost triple therapy with bismuth for Helicobacter pylori positive peptic ulcer disease. United European Gastroenterology Week 1995:A551 (abstract).
47. Miyaji H., Azuma T., Ito S., et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxicillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther. 11:1997;1131-1136.
48. Ching C.K., Leung K.P., Yung R.W.H., et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut. 38:1996;675-678.
49. Powell K.U., Bell G.D., Bowden A.F., et al. An effective one-week Helicobacter pylori eradication therapy using omeprazole, clarithromycin and metronidazole. Br J Clin Res. 6:1995;85-90.
50. Yang JC, Chen WH, Wang JT, et al. Comparison of three non-bismuth triple therapy for the eradication of Helicobacter pylori. United European Gastroenterology Week 1995:A1993 (abstract).
51. Lerang F., Moum B., Haug J.B., et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease Does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol. 92:1997;248-253.
52. Xia H.X., Buckley M., Hyde D., et al. Effects of antibiotic-resistance on clarithromycin combined triple therapy for Helicobacter pylori. Gut. 37:1995;A55. (abstract).
53. Cayla R., Zerbib F., De Mascare A., et al. Dual therapy with high dose of omeprazole verses triple therapy using omeprazole in combination with two antibiotics for H. pylori eradication Results of a randomized controlled trial among 100 patients . Am J Gastroenterol. 89:1994;1366. (abstract).
54. Thijs J.C., van Zwet A.A., Thijs W.J., et al. One week PPI triple therapy with omeprazole, amoxicillin, and tinidazole for Helicobacter pylori infection The significance of imidazole susceptibility . Aliment Pharmacol Therap. 11:1997;305-309.
55. Moayyedi P., Sahay P., Tompkins D.S., et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 7:1995;835-840.
56. Talbi P., Zerbib F., Cayla R., et al. Influence of nitroimidazole resistance on Helicobacter pylori eradication with the Italian one week triple therapy. Gastroenterology. 112:1997;A307. (abstract).
57. Georgopoulos S., Karatapanis S., Mentis A., et al. Comparison of two short-term, triple therapies based on clarithromycin in the eradication of Helicobacter pylori A randomized study with 6-month follow up . Gastroenterology. 112:1997;A125. (abstract).
58. Harris A.W., Pryce D.I., Gabe S.M., et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther. 10:1996;1005-1008.
59. Van Oijen A.H.A.M., Dekkers C.P.M., Festen H.P.M., et al. Lansaprozol, amoxicillin and metronidazole versus lansaprazole, amoxicillin and placebo for cure of H. pylori infection in patients with non ulcer dyspepsia. Gastroenterology. 122:1997;A321. (abstract).
60. Breurer T., Kim J.G., Gurer I.E., et al. Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole resistant Helicobacter pylori. Aliment Pharmacol Ther. 11:1997;523-527.
61. Bouchard S., Birac C., Lamouliatte H., et al. Correlation between the MIC's of metronidazole on Helicobacter pylori strains and the outcome of a lansoprazole-amoxicillin-metronidazole therapy. Gut. 39:(suppl 2):1996;A6. (abstract).
62. Peitz U., Nusch A., Tillenburg B., et al. High cure rate of H. pylori infection by one-week therapy with omeprazole, metronidazole and clarithromycin despite a negative impact by metronidazole resistance. Gut. 39:(suppl 2):1996;A5. (abstract).
63. Bardan K.D., Morton D., Slater D.N., et al. Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication. Aliment Pharmacol Ther. 12:1998;185-189.
64. Lamouliatte H., Florent Ch, Vicari F., et al. Effect of lansoprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori A randomized double blind multicentre study . Gastroenterology. 110:1996;A170. (abstract).
65. Lamouliatte H., Cayla R., Talbi P., et al. Randomised study comparing two seven days triple therapies with lansoprazole and low dose of clarithromycin plus amoxicillin or tinidazole for Helicobacter pylori eradication. Gastroenterology. 110:1996;A170. (abstract).
66. Schütze K., Hentschel E., Hirschl A.M. Duodenal ulcer healing after 7-day treatment with amoxicillin, metronidazole and omeprazole without acid suppression. Gut. 41:(suppl 1):1997;A98-A9. (abstract).
67. Buckley M.J.M., Xia H.X., Hyde D.M., et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci. 42:1997;2111-2115.
68. Moayyedi P., Tompkins D.S., Ragunathan P.L., et al. Relevance of metronidazole resistance in predicting failure of omeprazole, clarithromycin and tinidazole to eradicate Helicobacter pylori. Gut. 39:(suppl 3):1996;A141. (abstract).
69. Georgopoulos S., Karatapanis S., Vretou V., et al. Metronidazole resistance influences the efficacy of the short-term triple therapies, involving metronidazole, in the eradication of Helicobacter pylori. Gut. 39:(suppl 3):1996;A140. (abstract).
70. Georgopoulos S., Karatapanis S., Mentis A., et al. Influence of metronidazole resistance on the efficacy of two, short-term, triple therapies based on clarithromycin in the eradication of H. pylori. Gut. 39:(suppl 3):1996;A140-A141. (abstract).
71. Adamek R.J., Suerbaum S., Plaffenbach B., et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin - Influence on treatment outcome. Am J Gastroenterol. 93:1998;386-389.
72. Lamouliatte H., Cayla R., Zerbib F., et al. Dual therapy versus triple therapy for Helicobacter pylori eradication. Preliminary results of a randomized controlled trial. Gastroenterology. 106:1994;A120. (abstract).
73. De Korwin J.D., Joubert M., Bazin N., et al. Lansoprazole versus lansoprazole plus antibiotics in the treatment of Helicobacter pylori gastric infection. Gastroenterology. 104:1993;A67. (abstract).
74. Bell G.D., Powell K.U., Burridge S.M., et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 9:1995;41-46.
75. Bell G.D., Bate C.M., Axon A.T.R., et al. Addition of metronidazole to omeprazole/amoxicillin dual therapy increases the rate of Helicobacter pylori eradication A double blind, randomized trial . Aliment Pharmacol Ther. 9:1995;513-520.
76. Ström M, Sörberg M, Jönsson KA. Immediate repeat course of amoxicillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Aliment Pharmacol Ther 11:311-6.
77. Schwartz H., Krause R., Siepman N., et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection A short report . Helicobacter. 1:1996;251-255.
78. Labenz J., Idström J.P., Tillenburg B., et al. One week triple therapy for Helicobacter pylori is sufficient for relief of symptoms and healing of duodenal ulcers. Alimentary Pharmacol Ther. 11:1997;89-93.
79. Misiewicz J.J., Harris A.W., Bardhan K.D., et al. One-week triple therapy for Helicobacter pylori A multi-center comparative study . Gut. 41:1997;735-739.
80. Goh K.L., Parasakthi N., Chuah S.Y., et al. Comparison of two 1-week low-dose omeprazole triple therapies - Optimal treatment of Helicobacter pylori infection? Aliment Pharmacol Ther. 11:1997;1115-1118.
81. Yousfi M.M., El-Zimaity H.M.T., Cole R.A., et al. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther. 10:1996;119-122.
82. Tham T.C.K., Collins J.S.A., McCormick C., et al. Ranitidine and omeprazole and their combination with antibiotics in the eradication of Helicobacter pylori A randomized controlled trial . Gut. 37:1995;A55. (abstract).
83. Goh K.L., Parasakthi N., Chuah S.Y., et al. Combination amoxicillin and metronidazole with famotidine in the eradication of Helicobacter pylori - A randomized, double-blind comparison of a three times daily and twice daily regimen. Eur J Gastroenterol Hep. 9:1997;1091-1095.
84. Yang JC, Chen WH, Wang JT, et al. Comparison of three non-bismuth triple therapy for the eradication of Helicobacter pylori. United European Gastroenterology Week 1995:A1993 (abstract).
85. Borody T.J., Andrews P., Fracchia G., et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut. 37:1995;477-481.
86. De Boer W.A., Van Etten R.J.X.M., Schneeberger P.M. Four days lansaprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Gut. 41:(suppl 1):1997;A101. (abstract).
87. De Boer W.A., Driessen W.M.M., Jansz A.R., et al. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients Results of a randomized prospective single-center study . Eur J Gastroenterol. 7:1995;1189-1194.
88. Graham D.Y., Hoffman J., El-Zimaity H.M.T., et al. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 11:1997;935-938.
89. De Boer W.A., Van Etten R.J., Schade R.W., et al. 4-Day lansoprazole quadruple therapy A highly effective cure of Helicobacter pylori infection . Am J Gastroenterol. 22:1996;313-316.
90. De Boer W.A., Van Etten R.J.X.M., Lai J.Y.L., et al. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter. 3:1996;145-150.
91. Tucci A., Corinaldesi R., Stangellini V., et al. One-day therapy for treatment of Helicobacter pylori infection. Dig Dis Sci. 38:1993;1670-1673.
92. De Boer W.A., Van Etten R.J., Schade R.W., et al. One day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Aliment Pharmacol. 11:1997;109-112.
93. De Boer W.A., Driessen W.M., Tytgat G.N. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther. 9:1995;633-638.
94. Vautier G., Scott B.B. A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther. 11:1997;107-108.
95. Van der Hulst R.W.M., Van den Ende A., Homan A., et al. Influence of metronidazole resistance on efficacy of quadruple therapy for H. pylori infection. Gut. 42:1998;166-169.
96. De Boer S.Y., Siem T.H. Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 11:1997;1119-1121.
97. Tucci A., Poli L., Mazzoni C., et al. Week-end therapy for H. pylori eradication. Gastroenterology. 108:1995;A246. (abstract).
98. De Boer W.A., Van Etten R.J.X.M. Weekend lansoprazole-quadruple therapy for Helicobacter pylori infection. Gut. 41:(suppl 1):1997;A97. (abstract).
99. De Boer W.A., Haeck P.W.E., Mulder C.J.J. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate A randomised comparison between two 7-day triple therapies and a 14-day dual therapy . Eur J Gastroenterol Hepatol. 9:1997;A44. (abstract).
100. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 7:1986;177-188.
101. Eggar M., Davey Smith G. Misleading meta-analysis. Lessons from "an effective, safe, simple" intervention that wasn't. Br Med J. 310:1995;752-754.
102. Horwitz R.I. "Large-scale randomized evidence: Large simple trials and overview of trials": Discussion. A clinical perspective on meta-analyses. J Clin Epidemiol. 48:1995;41-44.
103. Naylor C.D. Meta-analysis and the meta-epidemiology of clinical research. Br Med J. 315:1997;617-619.
104. Bardhan K.D., Bayerdorffer E., Delchier J.P., et al. H. pylori eradication with omeprazole, metronidazole and amoxicillin The impact of drug dosing and resistance on efficacy - the homer story . Gastroenterology. 114:1998;A65. (abstract).
105. Midolo P.D., Turnidge J., Lambert J.R., et al. Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori. Diagn Microbiol and Infect Dis. 21:1995;135-140.
106. Midolo P.D., Bell J.M., Lambert J.R., et al. Antimicrobial resistance testing of Helicobacter pylori A comparison of E-test and disk diffusion methods . Pathology. 29:1997;411-414.
107. Van der Wouden E.J., De Jong A., Van Zwet A.A., et al. E-test compared to disk diffusion and breakpoint agar dilution in metronidazole susceptibility testing of Helicobacter pylori. Antiinfective Drugs Chemother. 16:1998;A95. (abstract).
108. Hachem C.Y., Clarridge J.E., Reddy R., et al. There are discrepancies between the results of antimicrobial susceptibility testing of Helicobacter pylori using the E-test compared to broth microdilution or disk diffusion. Gastroenterology. 108:1995;A106. (abstract).
109. Weissfield A., Kidd S., Fludas C., et al. Comparison of agar dilution vs E-test in the interpretation of antimicrobial susceptibility to H. pylori. Gastroenterology. 114:1998;A329. (abstract).
110. De Boer W.A., Tytgat G.N.J. 90% Cure; which anti-Helicobacter therapy can achieve this goal? Am J Gastroenterol. 90:1995;1381-1382. (editorial).
111. Graham D.Y. A reliable cure for H. pylori infection? Gut. 37:1995;154-156.
112. Van der Wouden E.J., Thijs J.C., Van Zwet A.A., et al. Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole for H. pylori infection. Gastroenterology. 114:1998;A323. (abstract).
113. Bardhan K.D., Morton D., Perry M.J., et al. Ranitidine bismuth citrate with clarithromycin given alone or with metronidazole for 7 days effectively eradicates H. pylori. Gastroenterology. 114:1998;A66. (abstract).
114. Perri F., Festa V., Clemente R., et al. Ranitidine bismuth citrate plus clarithromycin and metronidazole in a geographical area with high primary metronidazole resistance. Gastroenterology. 114:1998;A257. (abstract).
115. Chiba N., Rao B.V., Rademaker J.W., et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating H. pylori. Am J Gastroenterol. 87:1992;1716-1727.
116. Unge P., Berstad A. Pooled analysis of anti-Helicobacter pylori treatment options. Scan J Gastroenterol. 31:(suppl 220):1996;27-40.